game background

TORONTO – Jakob Poeltl, Kelly Olynyk and Davion Mitchell will all return to the Toronto Raptors lineup tonight against the Dallas Mavericks. Poeltl missed Toronto’s 129-92 loss to the visiting Oklahoma City Thunder on Thursday due to illness. Mitchell was listed as questionable with right hip stiffness after that loss, but Raptors head coach Dakro Rajakovic says he’s available against Dallas. It will be Olynyk’s first time playing in the 2024-25 season after missing the entire pre-season and first 23 games of the campaign with back spasms. Olynyk, who was born in Toronto but grew up in Kamloops, B.C., will add significant depth to the Raptors’ rotation. He averaged 12.7 points, 5.6 rebounds, and 4.6 assists in 28 games for Toronto last season after he was traded to the Raptors by the Utah Jazz on Feb. 8. This report by The Canadian Press was first published Dec. 7, 2024. Follow @jchidleyhill.bsky.social on BlueskyFORT WORTH, Texas (AP) — Longtime Republican U.S. Rep. Kay Granger of Texas is having "unforeseen health challenges” that have worsened in the final months of her more than two decades in Congress, a statement from her office said Monday. Granger, 81, has not cast a vote in Washington since July. In a statement provided by her office, Granger said she has been “navigating some unforeseen health challenges over the past year" but did not specify or elaborate. “However, since early September, my health challenges have progressed making frequent travel to Washington both difficult and unpredictable,” the statement said. Granger’s office did not immediately respond to questions emailed Monday about her condition or why they did not publicly disclose her health status earlier. Messages left with Granger's family also were not immediately returned. Granger announced in 2023 that she would not seek reelection, saying at the time that it was time for a new generation of leaders to step up. Granger also announced in March that she would step down as chair of the powerful House Appropriations Committee. First elected to Texas' 12th Congressional District in 1996, Granger was the first Republican woman elected to represent the state in the U.S. House. Before that, she was the mayor of Fort Worth. Her seat will be filled in January by Republican Craig Goldman , a former Texas House member, who was elected to the district that includes parts of Fort Worth, western Tarrant County and most of neighboring Parker County. The Associated PressPremier League ref David Coote WON’T appeal sacking after videos emerged of anti-Klopp rant and snorting white powder

Our high sports photos, like the ones above, put you in the middle of the action. Check them out by clicking anywhere in the collage to open the photo gallery. Don’t forget to share the gallery with friends and family. These photos are available for purchase in a variety of sizes and finishes – click the blue “GET PHOTO” link below any photo to see available options and make a purchase. Lehighvalleylive.com subscribers can also get free print-quality digital downloads of any image. Note : We are trying to make these galleries available as quickly as possible. The gallery may not be in its final form. If you only see a few photos, you are likely seeing an early version and more images will be added later. Please return and refresh the page to see additions. RECOMMENDED • lehighvalleylive .com Walmart just slashed $1,000 off this massive 75′′ Sony TV in an unreal Cyber Monday deal Dec. 1, 2024, 5:45 p.m. How to watch Phillipsburg football play for its first group championship Dec. 3, 2024, 2:45 p.m. Mobile users : For the best experience downloading high-resolution images (free and available to subscribers only) or making photo purchases, visit this page from a desktop or laptop computer. The lehighvalleylive.com high school sports newsletter is appearing in mailboxes weekly. Sign up now ! Follow us on social: Facebook | X (formerly Twitter) | Instagram

Juggernaut Marketing Wins the 2024 Quality Business Award for The Best Advertising Agency in Medford, OregonTORONTO - Utah’s NHL team was forced to walk to their game against the Maple Leafs after their bus got stuck in Toronto traffic Sunday night, prompting Premier Doug Ford to call the city’s gridlock “embarrassing.” The Utah Hockey Club posted on social media a video of team members marching to Scotiabank Arena, with player Maveric Lamoureux saying the bus was “not moving at all.” Several city streets had been closed during the day for the annual Santa Claus parade. “I think that’s a first for everyone,” Lamoureux quipped in the video as the group walked along the downtown streets. “Never saw that before.” The viral incident prompted Premier Doug Ford to call the road congestion “unacceptable,” highlighting his government’s plan to address the city’s gridlock through bike lane legislation. “We’re really focused on the congestion in Toronto,” he said Monday at an unrelated press conference. “It’s the worst congested city in North America, third worst in the entire world, even to the point last night it was embarrassing that the Utah Hockey Club has to get out of the bus and start walking to the hockey arena.” Ford said people are “avoiding downtown” due to the traffic, pointing to bike lanes as part of the problem. Ontario passed a divisive bike lane bill on Monday that will require municipalities to get the province’s approval to install bike lanes when they would remove a lane for vehicles. The bill also removes sections of bike lanes in Toronto and restores them as lanes for vehicle traffic. At a press conference on Monday, Toronto Mayor Olivia Chow pointed to the Santa Claus parade as the cause of Sunday’s gridlock. “All the big floats and the people flooding out from the Santa Claus parade was jamming that whole area,” Chow said. “It was just because of that reason.” Chow said while she’s glad the Leafs won the game, she’s sorry the Utah team got caught in the congestion. “Santa didn’t conspire together with the Leafs,” she said. Chow had said in September that the city’s traffic congestion measures are working, according to data that shows travel times along certain corridors have sped up. The Utah Hockey Club’s walk to the arena wasn’t the first time a Toronto visitor had to ditch their vehicle to make it to an event on time. In June, former One Direction band member Niall Horan had to walk through bumper-to-bumper traffic to get to his concert at Scotiabank Arena. “Traffic’s too bad in Toronto, so we’re walking to the venue,” he said in a social media post at the time. “In all the years playing shows, I don’t think I ever walked to a venue.” This report by The Canadian Press was first published Nov. 25, 2024.

Notation Labs Secures $2 Million Credit Facility to Accelerate Production of QwelTM, a Cutting-Edge Lead Detection and Prevention SystemNEW YORK (AP) — U.S. stock indexes got back to climbing on Wednesday after the latest update on inflation appeared to clear the way for more help for the economy from the Federal Reserve . The S&P 500 rose 0.8% to break its first two-day losing streak in nearly a month and finished just short of its all-time high. Big Tech stocks led the way, which drove the Nasdaq composite up 1.8% to top the 20,000 level for the first time. The Dow Jones Industrial Average, meanwhile, lagged the market with a dip of 99 points, or 0.2%. Stocks got a boost as expectations built that Wednesday’s inflation data will allow the Fed to deliver another cut to interest rates at its meeting next week. Traders are betting on a nearly 99% probability of that, according to data from CME Group, up from 89% a day before. If they’re correct, it would be a third straight cut by the Fed after it began lowering rates in September from a two-decade high. It’s hoping to support a slowing job market after getting inflation nearly all the way down to its 2% target. Lower rates would give a boost to the economy and to prices for investments, but they could also provide more fuel for inflation. “The data have given the Fed the ‘all clear’ for next week, and today’s inflation data keep a January cut in active discussion,” according to Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management. Expectations for a series of cuts to rates by the Fed have been one of the main reasons the S&P 500 has set an all-time high 57 times this year , with the latest coming last week. The biggest boosts for the index on Wednesday came from Nvidia and other Big Tech stocks. Their massive growth has made them Wall Street’s biggest stars for years, though other kinds of stocks have recently been catching up somewhat amid hopes for the broader U.S. economy. Tesla jumped 5.9% to finish above $420 at $424.77. It’s a level that Elon Musk made famous in a 2018 tweet when he said he had secured funding to take Tesla private at $420 per share . Stitch Fix soared 44.3% after the company that sends clothes to your door reported a smaller loss for the latest quarter than analysts expected. It also gave financial forecasts for the current quarter that were better than expected, including for revenue. GE Vernova rallied 5% for one of the biggest gains in the S&P 500. The energy company that spun out of General Electric said it would pay a 25 cent dividend every three months, and it approved a plan to send up to another $6 billion to its shareholders by buying back its own stock. On the losing end of Wall Street, Dave & Buster’s Entertainment tumbled 20.1% after reporting a worse loss for the latest quarter than expected. It also said CEO Chris Morris has resigned, and the board has been working with an executive-search firm for the last few months to find its next permanent leader. Albertsons fell 1.5% after filing a lawsuit against Kroger, saying it didn’t do enough for their proposed $24.6 billion merger agreement to win regulatory clearance. Albertsons said it’s seeking billions of dollars in damages from Kroger, whose stock rose 1%. A day earlier, judges in separate cases in Oregon and Washington nixed the supermarket giants’ merger. The grocers contended a combination could have helped them compete with big retailers like Walmart, Costco and Amazon, but critics said it would hurt competition. After terminating the merger agreement with Kroger, Albertsons said it plans to boost its dividend 25% and increased the size of its program to buy back its own stock. Macy’s slipped 0.8% after cutting some of its financial forecasts for the full year of 2024, including for how much profit it expects to make off each $1 of revenue. All told, the S&P 500 rose 49.28 points to 6,084.19. The Dow dipped 99.27 to 44,148.56, and the Nasdaq composite rallied 347.65 to 20,034.89. In the bond market, the yield on the 10-year Treasury rose to 4.27% from 4.23% late Tuesday. The two-year Treasury yield, which more closely tracks expectations for the Fed, edged up to 4.15% from 4.14%. In stock markets abroad, indexes rose across much of Europe and Asia. Hong Kong’s Hang Seng was an outlier and slipped 0.8% as Chinese leaders convened an annual planning meeting in Beijing that is expected to set economic policies and growth targets for the coming year. South Korea’s Kospi rose 1%, up for a second straight day as it climbs back following last week’s political turmoil where its president briefly declared martial law. AP Writers Matt Ott and Zimo Zhong contributed.Stanley Black & Decker Inc. stock underperforms Wednesday when compared to competitorsDetroit's iconic Renaissance Center could see 2 towers razed in $1.6B redevelopment plan

Special Counsel Jack Smith on Monday moved to dismiss the federal cases against US President-elect Donald Trump -- including one for election subversion -- citing an official policy of not prosecuting a sitting president. Trump, 78, was accused of conspiring to overturn the results of the 2020 election he lost to Joe Biden and mishandling classified documents after leaving the White House, but neither case ever came to trial. Smith, in a filing with the district judge in Washington presiding over the election case, said it should be dropped in light of the long-standing Justice Department policy of not indicting or prosecuting a sitting president. He cited the same reasoning in withdrawing his appeal of a ruling by a district judge, a Trump appointee, who dismissed the classified documents case earlier this year. Smith asked District Judge Tanya Chutkan to dismiss the election interference case "without prejudice" -- leaving open the possibility it could be revived after Trump leaves office four years from now. The special counsel paused the election interference case this month after Trump defeated Vice President Kamala Harris in the November 5 presidential election. "The Government's position on the merits of the defendant's prosecution has not changed," Smith said in the filing with Chutkan. "But the circumstances have." "It has long been the position of the Department of Justice that the United States Constitution forbids the federal indictment and subsequent criminal prosecution of a sitting President," Smith said. "As a result this prosecution must be dismissed before the defendant is inaugurated." In a separate filing, Smith said he was withdrawing his appeal of the dismissal of the classified documents case against Trump but pursuing the case against his two co-defendants, Trump valet Walt Nauta and Mar-a-Lago property manager Carlos De Oliveira. Trump, in a post on Truth Social, said the cases were "empty and lawless, and should never have been brought." "Over $100 Million Dollars of Taxpayer Dollars has been wasted in the Democrat Party's fight against their Political Opponent, ME," he said. "Nothing like this has ever happened in our Country before." Trump is accused of conspiracy to defraud the United States and conspiracy to obstruct an official proceeding -- the session of Congress called to certify Biden's win, which was violently attacked on January 6, 2021 by a mob of the then-president's supporters. Trump is also accused of seeking to disenfranchise US voters with his false claims that he won the 2020 election. The former and incoming president also faces two state cases -- in New York and Georgia. He was convicted in New York in May of 34 counts of falsifying business records to cover up a hush money payment to porn star Stormy Daniels on the eve of the 2016 election to stop her from revealing an alleged 2006 sexual encounter. Judge Juan Merchan has postponed sentencing while he considers a request from Trump's lawyers that the conviction be thrown out in light of the Supreme Court ruling in July that an ex-president has broad immunity from prosecution. In Georgia, Trump faces racketeering charges over his efforts to subvert the 2020 election results in the southern state, but that case will likely be frozen while he is in office. cl/bgs

Taiwan reports 14 Chinese warships and 4 balloons near the island

Believe it or not, Cowboys might have hope yet after chaotic win at Washington

General Election candidate Eoghan Kenny has said he suffered an epileptic seizure just before going on air on RTÉ Radio last week. The Labour Party candidate for Cork North Central said he is “proud to be an epileptic” and recalled the experience on social media this evening. “Politicians are normal. That's a phrase that I've inherited this week,” said the Cork County Councillor. He revealed he suffered an epileptic seizure in the RTÉ studios last Tuesday, just before going on RTÉ Radio One’s Drivetime . "The politicians in the room, what some might consider rivals of mine in the upcoming general election, I now consider them colleagues of mine in the political sphere,” he said. “They came to my assistance, along with the staff of RTÉ and the two paramedics as well. “Just to say that I'm very grateful for the assistance that I received but I am absolutely perfect and driving on my campaign. “It proves a point that people with medical conditions can go into the public eye and represent people, whether it be locally or nationally,” he said. We need your consent to load this Social Media content. We use a number of different Social Media outlets to manage extra content that can set cookies on your device and collect data about your activity. Mr Kenny highlighted that his condition doesn’t affect his job as a public representative. "It's important to realise that it hasn't affected my job since February, since I became a councillor, and that it's a condition that I have to live with and a condition that I'm very proud to live with,” he added. The general election candidate from Mallow praised Epilepsy Ireland – a charity supporting people living with the condition. He also shared advice on how to help someone who suffers an epileptic seizure. “I'm very proud of the fact that Epilepsy Ireland are great advocates for people who are suffering with epilepsy to over 1,200 people in Cork North-Central. “I'm grateful for the work that they do in promoting epilepsy awareness and I would encourage everybody to remember these three words: stay, time and safe. "Stay with the person, time the seizure and make sure the person is safe. "Of course, I wanted to own this story myself. It's my story to tell and I didn't want it to be told by anybody else,” he added. "I'm proud to say that I'm very, very good now after my seizure on Tuesday. "I'm hoping to win this seat in Cork North-Central, but I can only do that with your support next Friday,” he added.Rogers Communications Inc. Cl B stock outperforms market despite losses on the day

TikTok is challenging the federal government’s order to shut down its operations in Canada. The company filed in documents in Federal Court in Vancouver on Thursday. The government ordered the dissolution of TikTok’s Canadian business in November after a national security review of the Chinese company behind the social media platform. That means TikTok must “wind down” its operations in Canada, though the app will continue to be available to Canadians. TikTok wants the court to overturn the government’s order and to place a pause on the order while the court hears the case. It is claiming the minister’s decision was “unreasonable” and “driven by improper purposes.” The review was carried out through the Investment Canada Act, which allows the government to investigate any foreign investment with potential to harm national security. Industry Minister François-Philippe Champagne said in a statement at the time the government was taking action to address “specific national security risks,” though it didn’t specify what those risks were. TikTok’s filing says Champagne “failed to engage with TikTok Canada on the purported substance of the concerns that led to the (order.)” The company argues the government ordered “measures that bear no rational connection to the national security risks it identifies.” It says the reasons for the order “are unintelligible, fail to reveal a rational chain of analysis and are rife with logical fallacies.” The company’s law firm, Osler Hoskin & Harcourt LLP, declined to comment, while Champagne’s office did not immediately respond to a request for comment. A TikTok spokesperson said in a statement that the order would “eliminate the jobs and livelihoods of our hundreds of dedicated local employees — who support the community of more than 14 million monthly Canadian users on TikTok, including businesses, advertisers, creators and initiatives developed especially for Canada.” This report by The Canadian Press was first published Dec. 10, 2024. Darryl Greer and Anja Karadeglija, The Canadian PressAcute Respiratory Distress Syndrome Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | RS BioTherapeutics, AVM Biotech, Cynata Therapeu 12-23-2024 11:56 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Respiratory Distress Syndrome pipeline constitutes 50+ key companies continuously working towards developing 50+ Acute Respiratory Distress Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. "Acute Respiratory Distress Syndrome Pipeline Insight, 2024 [ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market. Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report: * Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years. * Acute Respiratory Distress Syndrome companies working in the treatment market are RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompe Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy's and St Thomas' NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment * Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years. * In October 2024, BioAegis Therapeutics, an innovative biotech company focused on developing therapies for inflammatory diseases, is excited to announce the enrollment of the first patient in its Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress Syndrome (ARDS) (NCT05947955). * In December 2023, Thermo Fisher Scientific Inc.'s PPD clinical research division, a global leader in scientific solutions, has been chosen by the Biomedical Advanced Research and Development Authority (BARDA) to conduct the inaugural BARDA-backed Phase II platform clinical trial. This trial aims to explore various therapeutic avenues for addressing acute respiratory distress syndrome (ARDS). BARDA operates under the Administration for Strategic Preparedness and Response (ASPR), situated within the U.S. Department of Health and Human Services (HHS). Acute Respiratory Distress Syndrome Overview Acute Respiratory Distress Syndrome (ARDS) is a severe condition in which the lungs become inflamed and fill with fluid, leading to difficulty breathing and low oxygen levels in the blood. It can result from various causes, including infections, trauma, pneumonia, or inhalation of harmful substances. Symptoms include shortness of breath, rapid breathing, and low oxygen levels. ARDS is a medical emergency that often requires hospitalization, with treatments including oxygen therapy, mechanical ventilation, and addressing the underlying cause. In severe cases, ARDS can lead to organ failure and may be life-threatening. Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight [ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include: * RSBT-001: RS BioTherapeutics * AVM0703: AVM Biotechnology * CYP 001: Cynata Therapeutics * AV 001: Vasomune Therapeutics * ALT-100: Aqualung Therapeutics * STSA-1002: Staidson (Beijing) Biopharmaceuticals * GEn-1124: GEn1E Lifesciences * Descartes 30: Cartesian Therapeutics * Rhu-pGSN: BioAegis Therapeutics Inc. * ExoFlo: Direct Biologics, LLC * Reparixin 600mg: Dompe Farmaceutici S.p.A * Centhaquine: Pharmazz, Inc. * ALT-100 mAb: Aqualung Therapeutics Corp. * MRG-001: MedRegen LLC * TTI-0102: Thiogenesis Therapeutics, Inc. * Dexamethasone: Hospital Universitario Infanta Leonor * Isoflurane: Guy's and St Thomas' NHS Foundation Trust * Pirfenidone/Placebo: Fujian Medical University * Trimodulin: Biotest * AeroFact: Aerogen Pharma Limited * Ibudilast: MediciNova * Poractant Alfa: NorthShore University HealthSystem * Tozorakimab: AstraZeneca * L-citrulline: Asklepion Pharmaceuticals Acute Respiratory Distress Syndrome Route of Administration Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as * Oral * Parenteral * Intravitreal * Subretinal * Topical * Molecule Type Acute Respiratory Distress Syndrome Molecule Type Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as * Monoclonal Antibody * Peptides * Polymer * Small molecule * Gene therapy * Product Type Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment * Acute Respiratory Distress Syndrome Assessment by Product Type * Acute Respiratory Distress Syndrome By Stage and Product Type * Acute Respiratory Distress Syndrome Assessment by Route of Administration * Acute Respiratory Distress Syndrome By Stage and Route of Administration * Acute Respiratory Distress Syndrome Assessment by Molecule Type * Acute Respiratory Distress Syndrome by Stage and Molecule Type DelveInsight's Acute Respiratory Distress Syndrome Report covers around 50+ products under different phases of clinical development like * Late-stage products (Phase III) * Mid-stage products (Phase II) * Early-stage product (Phase I) * Pre-clinical and Discovery stage candidates * Discontinued & Inactive candidates * Route of Administration Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies [ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include: Key companies developing therapies for Acute Respiratory Distress Syndrome are - Fisher & Paykel Healthcare Limited, NRx Pharmaceuticals, Inc., Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Company, Athersys, United Therapeutics, Apeptico Forschung, HEALIOS K.K, Dragerwerk AG & Co. KGaA, ALung Technologies, Inc ( LivaNova PLC), and others. Acute Respiratory Distress Syndrome Pipeline Analysis: The Acute Respiratory Distress Syndrome pipeline report provides insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same. * It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment. * Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. * Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies [ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Acute Respiratory Distress Syndrome Pipeline Market Drivers * Rising incidence of Acute Respiratory Distress Syndrome, the rising geriatric population are some of the important factors that are fueling the Acute Respiratory Distress Syndrome Market. Acute Respiratory Distress Syndrome Pipeline Market Barriers * However, increasing Cost of Treatment Therapeutics, lack of Skilled Professionals and other factors are creating obstacles in the Acute Respiratory Distress Syndrome Market growth. Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight * Coverage: Global * Key Acute Respiratory Distress Syndrome Companies: RS BioTherapeutics, AVM Biotechnology, Cynata Therapeutics, Vasomune Therapeutics, Aqualung Therapeutics, Staidson (Beijing) Biopharmaceuticals, GEn1E Lifesciences, Cartesian Therapeutics, BioAegis Therapeutics Inc., Direct Biologics, LLC, Dompe Farmaceutici S.p.A, Pharmazz, Inc., Aqualung Therapeutics Corp., MedRegen LLC, Thiogenesis Therapeutics, Inc., Hospital Universitario Infanta Leonor, Guy's and St Thomas' NHS Foundation Trust, Fujian Medical University, Biotest, Aerogen Pharma Limited, MediciNova, NorthShore University HealthSystem, AstraZeneca, Asklepion Pharmaceuticals, and others * Key Acute Respiratory Distress Syndrome Therapies: RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN, ExoFlo, Reparixin 600mg, Centhaquine, ALT-100 mAb, MRG-001, TTI-0102, Dexamethasone, Isoflurane, Pirfenidone/Placebo, Trimodulin, AeroFact, Ibudilast, Poractant Alfa, Tozorakimab, L-citrulline, and others * Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies * Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials [ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Table of Contents 1. Acute Respiratory Distress Syndrome Report Introduction 2. Acute Respiratory Distress Syndrome Executive Summary 3. Acute Respiratory Distress Syndrome Overview 4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment 5. Acute Respiratory Distress Syndrome Pipeline Therapeutics 6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III) 7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II) 8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I) 9. Acute Respiratory Distress Syndrome Preclinical Stage Products 10. Acute Respiratory Distress Syndrome Therapeutics Assessment 11. Acute Respiratory Distress Syndrome Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Acute Respiratory Distress Syndrome Key Companies 14. Acute Respiratory Distress Syndrome Key Products 15. Acute Respiratory Distress Syndrome Unmet Needs 16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers 17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion 18. Acute Respiratory Distress Syndrome Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=acute-respiratory-distress-syndrome-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-rs-biotherapeutics-avm-biotech-cynata-therapeu ] Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.

Prosecutor moves to drop federal cases against Trump

Dunnes Stores shoppers rushing to the tills for all-black outfit for €45 that is perfect for the office and night out

None

The Left doesn't like opposing viewpoints. That's not news. But what's really telling is the way the Left treats people from typically Left-leaning groups who don't toe their political line. Whether it's women or Blacks or actors, the Left thinks they own these groups and their votes -- and they get downright nasty when someone strays from the flock. This writer has been a fan of Zachary Levi since he starred on 'Chuck', and -- even though she doesn't know him personally -- he seems like a genuinely nice guy. But he's committed the ultimate political sin: he supports Donald Trump . Doing that publicly takes guts, because it'll likely cost him jobs and friendships (cause Hollywood isn't exactly a bastion of tolerance). And here's Variety proving the point by publishing this nasty high-school mean girl piece from a former co-star of Levi's: “I never liked him," Laura Benanti says of Zachary Levi. "Everyone was like, ‘He’s so great!’ And I was like, ‘No, he’s not. He’s sucking up all the f---ing energy in this room. He wants to mansplain everybody’s part to them.'” https://t.co/tIS9jszVaB This writer also really likes movies and Broadway and has never heard of Laura Benanti, for what it's worth. This is what happens when you have the stones to break the narrative. Hold the line, Zachary Hold the line. Who's Laurie Benanti? Serious question. Exactly. It sounds like she’s just bitter and unhappy. This article makes her sound non-credible. Was that the intent of the article? To smear Levi. Nothing more. Are there still people who don't know that the second someone uses the term mansplain they are a childish dimwit with nothing to offer? Mansplain: He was smarter and more articulate, and I'm mad There is no such thing as 'mansplaining.' It's a word hypersensitive women use when they don't want men talking to them. Dear Variety, you guys are despicable hatemongers. You have helped poison the industry Hold the line Zachary, you are a hero. Yes, he is. I’ve heard of @ZacharyLevi . However, I’ve never hear of Laura Benanti. The era of attacking past co-stars as a means to impress the judges at the Victim Olympics is over. It does not result in more work. In fact, it simply telegraphs one’s capacity to torpedo projects, past,... https://t.co/LXIAaux59Z All of this. She's clearly mad at his vaccine stance but has nothing specifically bad to say about him so it's just vague gobbledygook with "mansplaining" thrown in there because that one always works with no details necessary. https://t.co/3JatjSYc3y pic.twitter.com/TUCelf7dD7 And Variety decided to run with this. If everyone liked him and you didn’t, maybe... I dunno... you’re the problem? https://t.co/nI5tWHHNIs Yeah, she might be the problem here. This writer is willing to bet Levi will have nothing but nice things to say about Benanti, proving that he's the good guy and the bigger person.

With Donald Trump headed back to the White House and hawkish Sen. Marco Rubio picked as his secretary of state, the island’s leadership is bracing for what comes next. Hunger, blackouts, hurricanes and earthquakes already have the country reeling, and speculation is building that the incoming administration will further tighten the screws. “There’s nothing very positive that can be expected from a Trump administration,” said Omar Everleny Perez, a Cuban economist based in Havana who has taught at Harvard and Columbia universities and worked as a visiting scholar at the Federal Reserve Bank of Atlanta. “In the minds of most Cubans is the thought of getting out.” During the presidential campaign and on Capitol Hill, Trump and Rubio talked about the need for regime change in Havana. For the Florida senator, the issue has particular significance: He’s the son of Cuban immigrants and made his heritage and opposition to communism central to his conservative political identity. That makes it all the more likely Trump will bring back the “maximum pressure” approach of his first term, when he tightened sanctions and scared off investors by returning Cuba to a list of state sponsors of terrorism. A spokesperson for the incoming administration declined to comment directly on policy toward Cuba, noting Trump was elected “to lead our country and restore peace through strength around the world.” Trump is the first Republican presidential candidate since 1988 to win Miami-Dade County, home to many Cuban exiles. The island of 11 million people is staggering under inflation, food shortages, crop failure and the repeated collapse of its power grid. A full 10% of the population fled the country since 2020. As public discontent grows, Cuba stepped up arrests of dissidents and warned citizens not to protest. Trump’s team likely will “look for creative ways to exacerbate the chasm that is existing right now in Cuba between the people and the regime,” said Jose Cardenas, who worked on Latin America issues under former President George W. Bush and now serves as an independent consultant in Washington. Though President Joe Biden left much of Trump’s prior Cuba policy intact, Cardenas expects the new administration will quickly take action against President Miguel Diaz-Canel in Havana and Nicolas Maduro in Caracas, Venezuela. Rubio will “seek to regain some momentum and go on the offensive — but not in a provocative, ham-handed way,” Cardenas said. It isn’t yet clear how the incoming administration’s stance toward Latin America will be affected by Trump’s pledge to round up migrants and deport them en masse. Rubio will have to figure out how to navigate that promise along with the U.S.’s long-standing practice of offering an escape to people fleeing far-left regimes in the region, according to Ana Sofia Pelaez, co-founder of the Miami Freedom Project, which works with migrants in South Florida. In 2023, the Biden administration allowed Cuban, Venezuelan, Nicaraguan and Haitian migrants to apply for two-year emergency visas. More than 125,000 Cubans entered the U.S. under the program. On top of economic and humanitarian woes, Cuba also faces questions of legitimacy, according to Andres Pertierra, a Cuban-American historian who was doing doctoral research on the island for eight months this year until the power crisis forced the archives to close. Since the revolution led by Fidel Castro, the government ruled with a tacit bargain: Caribbean communism couldn’t provide the same level of material goods as U.S. capitalism, but it would build a robust social safety net. It would also foster a sense of collective pride, despite the imposition of a security state that severely restricts political rights. That setup unraveled, and “this is probably the biggest point of weakness and vulnerability in the government’s history since 1959, not least because Fidel is not there,” Pertierra said from Madison, Wis. The Cuban Embassy in Washington didn’t respond to a request for comment. In almost every regard, the situation in Cuba is worse now than it was in the 1990s, after the fall of the Soviet Union brought hunger and hardship. “Education is imploding, health care is catastrophic,” said Andres Pertierra, a Cuban-American historian who was doing doctoral research on the island for eight months this year until the power crisis forced the archives to close. “There’s no medicine, there’s no equipment, the infrastructure is falling apart.” That Cuban society is now divided into those with access to hard currency — often thanks to relatives abroad — and those without, which is fueling increasing discontent. Those with enough money can still buy food. But while allowing the nascent private sector to import and sell groceries prevented the weight loss Cubans suffered in the late 1990s, it also highlights “the inequality and the broken promises of the system,” said Pertierra, the son of a lawyer who defended Elian Gonzalez’s return to Cuba in a bitter custody case against the boy’s Miami relatives more than two decades ago. State-run media recently provided a grim snapshot of the hunger crisis: Some 1,615 people were convicted of illegally killing cows this year, risking prison terms of up to 10 years. Everleny Perez argued the Cuban regime’s best chance of surviving the next Trump administration is for the government to make good on its promise to support the private sector.Stock market today: Wall Street gets back to climbing, and the Nasdaq tops 20,000